We distribute our research widely to institutional and retail investors through various channels, including our proprietary database, website, and other platforms (such as Bloomberg, Thomson Reuters and Factset).

We are fully MiFID II compliant. Our research is paid for by our corporate clients, and we do not carry out any execution business.

Published reports can be obtained by searching our Research Library below, or directly from the relevant Company Pages.

Advanced search
Date range (dd-mm-yyyy)

Nexstim

First steps on path towards longer-term profitability

Update | 02 March 2022

Redx Pharma

Building on an impressive track-record

Outlook | 17 February 2022

Redx Pharma

FY21 results: a year of continuing delivery

Update | 27 January 2022

Allergy Therapeutics

FDA green lights VLP Peanut vaccine Phase I trial

Lighthouse | 26 January 2022

Arecor Therapeutics

Formulation expertise exemplified in diabetes

Update | 20 January 2022

ANGLE

FDA approval awaited, LDT data expected H122

Update | 17 January 2022

Allergy Therapeutics

Commercialising and developing a differentiated portfolio

Update | 13 January 2022

Nexstim

Admirable execution on 2021 strategic goals

Update | 12 January 2022

Avacta

AffiDX LFT sales paused to improve Omicron detection

Lighthouse | 10 January 2022

Avacta

Consumer testing CE mark received for AffiDX LFT

Lighthouse | 22 December 2021
1 2 3 4 5 6 7 8 9 10 >
311 results found.